{"nctId":"NCT00714688","briefTitle":"A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder","startDateStruct":{"date":"2008-02"},"conditions":["Attention Deficit/ Hyperactivity Disorder"],"count":279,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: prolonged release (PR) OROS methylphenidate 54 mg"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: prolonged release (PR) OROS methylphenidate 72 mg"]},{"label":"003","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"prolonged release (PR) OROS methylphenidate 54 mg","otherNames":[]},{"name":"prolonged release (PR) OROS methylphenidate 72 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition (DSM-IV) and confirmed by the Conners' Adult ADHD Diagnostic Interview for DSM IV\n* Described chronic course of ADHD symptomatology from childhood to adulthood, with some symptoms present before age 7 years and continue to meet DSM-IV criteria at the time of assessment\n* CAARS score of at least or equal to 24 as determined by investigator at screening visit\n* Patient agrees to take only the supplied study drug as treatment for ADHD during the study\n* Patient agrees not to initiate a new behavioral modification program during the study or if currently using a behavioral modification program agrees not to change this program during the study.\n\nExclusion Criteria:\n\n* Known to be a non-responder to methylphenidate, or patient has a child known to be a non-responder to methylphenidate\n* Has been treated with any methylphenidate-containing medication within 1 month of screening visit\n* Participation in and premature withdrawal from 42603ATT3002, CR002479 or 42603ATT3004, CR011068 study\n* Known allergy or hypersensitivity to methylphenidate, or components of PR OROS methylphenidate\n* Any clinically unstable psychiatric condition including, but not limited to the following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder (OCD), anti-social personality disorder, borderline personality disorder.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Attention Deficit/Hyperactivity Disorder (ADHD) Symptoms Total Score of the Conners Adult ADHD Rating Scale (CAARS)","description":"The primary endpoint was the change in the ADHD symptoms total score of the investigator-rated CAARS from baseline to the last assessment in the double-blind treatment period. CAARS assesses ADHD symptoms and behaviors in adults using a scale ranging from 0 (best) to 54 (worst). For subjects without a post-baseline efficacy measurement, a change of 0 units was imputed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":"6.05"},{"groupId":"OG001","value":"35.6","spread":"6.75"},{"groupId":"OG002","value":"37.3","spread":"6.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":"10.59"},{"groupId":"OG001","value":"23.0","spread":"11.07"},{"groupId":"OG002","value":"21.6","spread":"10.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4","spread":"11.03"},{"groupId":"OG001","value":"-12.5","spread":"10.38"},{"groupId":"OG002","value":"-15.7","spread":"10.80"}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Global Impression-Severity (CGI-S) From Baseline to End of Treatment","description":"The CGI-S rating scale is used to rate the severity of a subject's illness on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe illness). The change in CGI-S was assessed from baseline to end of treatment (week 13 or or last post-baseline assessment)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"-1.0","spread":null},{"groupId":"OG002","value":"-1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression-Change (CGI-C)","description":"The CGI-C rating scale is used to rate the change in severity of the subject's illness compared to baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"2.5","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Conners Adult ADHD Rating Scale Self Report Short Version (CAARS-S:S) Total Score","description":"The CAARS-S:S is a 26-item self-report scale that measures symptoms based on the DSM-IV criteria for ADHD. Respondents were asked to rate items pertaining to their behavior/problems using the following 4-point scale (from 0 = Not at all, never; to 3 = Very much, very frequently). The CAARS-S:S total score range is from 0 (best) to 78 (worse). The change in CAARS-S:S was assessed from baseline to end of treatment (week 13 or or last post-baseline assessment)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","spread":"11.64"},{"groupId":"OG001","value":"-12.8","spread":"13.42"},{"groupId":"OG002","value":"-12.6","spread":"13.84"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":97},"commonTop":["Headache","Decreased Appetite","Insomnia","Nausea","Nasopharyngitis"]}}}